DaShenLin Pharmaceutical Group Co., Ltd.SSE: 603233

in 2026

Jun 25, 2026 · Issued by DaShenLin Pharmaceutical Group Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 25, 2026 · 1 page · Chinese

On 6ix: 6ix.com/news/in-2026-4

Release

Announcement on Follow-up Rating Results of "Dashenlin Convertible Bonds” in 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

DaShenLin Pharmaceutical Group Co., Ltd. on 6ix

Earlier from DaShenLin Pharmaceutical

Announcement on Adjustment of the Conversion Price of the “Dashenlin Convertible Bonds"Jun 18
Indicative Announcement on Suspending Conversion of “Dashenlin Convertible Bonds" during the Implementation of Dividend Distribution for 2025Jun 11
Indicative Announcement on Impending Expiration of 2020 Employee Stock Ownership PlanMay 28
Announcement on Resolutions of the 2025 Annual General MeetingMay 19
Indicative Announcement on Change of the Meeting Date of the 2025 Annual General MeetingMay 12

Later from DaShenLin Pharmaceutical

Announcement on Progress in Providing Guarantee for SubsidiaryJun 26
Announcement on Conversion Result of Convertible Bonds and Share ChangesJul 2
Announcement on Reply to the Inquiry Letter on the Company's 2025 Annual ReportJul 21
Notice on Convening the 2nd Extraordinary General Meeting in 2026Aug 25
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Sep 12

All DaShenLin Pharmaceutical news releases

Follow DaShenLin Pharmaceutical into a list and get an email when it puts out news.

Follow DaShenLin Pharmaceutical